1. Telomeres and telomerase as novel drug targets: reflections on the 2009 Nobel Prize in Physiology or Medicine

   • Meng Dong
   • Thomas E. Mürdter
   • Ulrich Klotz

   Editorial 21 November 2009 Pages: 1 - 3

2. HTR1B as a risk profile maker in psychiatric disorders: a review through motivation and memory

   • Antonio Drago
   • Silvia Alboni
   • Alessandro Serretti

   Review Article 07 October 2009 Pages: 5 - 27

   

3. Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy

   • Morten A. Karsdal
   • Inger Byrjalsen
   • Claus Christiansen

   Clinical Trial 08 October 2009 Pages: 29 - 37

   

4. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency

   • Jan Regnstrom
   • Franz Koenig
   • Spiros Vamvakas

   Special Article 20 November 2009 Pages: 39 - 48

5. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials

   • Mao Mao An
   • Zui Zou
   • Yuan Ying Jiang

   Pharmacodynamics 21 November 2009 Pages: 49 - 59

   

6. CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients

   • Wei Zhang
   • Yan-Zi Chang
   • Jie Zhang

   Pharmacogenetics 26 September 2009 Pages: 61 - 66

   

7. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis

   • Julian Jenkins
   • Daphne Williams
   • Valerie S. Kitchen

   Pharmacokinetics and Disposition 16 September 2009 Pages: 67 - 76

   

8. Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1−48 months

   • John T. Mondick
   • Brendan M. Johnson
   • J. Frank Hoke

   Pharmacokinetics and Disposition 02 October 2009 Pages: 77 - 86

   

9. Drug utilisation on a preterm and neonatal intensive care unit in Germany: a prospective, cohort-based analysis

   • Antje Neubert
   • Kristin Lukas
   • Wolfgang Rascher

   Pharmacoepidemiology and Prescription 16 September 2009 Pages: 87 - 95

   

10. Adverse interaction of warfarin and paracetamol: evidence from a post-mortem study

    • Terhi Launiainen
    • Antti Sajantila
    • Ilkka Ojanperä

    Pharmacoepidemiology and Prescription 25 September 2009 Pages: 97 - 103

    

11. Erratum to: HTR1B as a risk profile maker in psychiatric disorders: a review through motivation and memory

    • Antonio Drago
    • Silvia Alboni
    • Alessandro Serretti

    Erratum 18 November 2009 Pages: 105 - 105

12. Pharmacogenomic adaptation of antiretroviral therapy: overcoming the failure of lopinavir in an African infant with CYP2D6 ultrarapid metabolism

    • Matthias Gorny
    • Stephanie Röhm
    • Tim Niehues

    Letter to the Editors 20 November 2009 Pages: 107 - 108